| --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------| | | Exhibit 99.1 | | | | | | | | | | | | | | BIOCERES CROP SOLUTIONS CORP. | | | Unaudited interim condensed consolidated financial statements as of March 31, 2024 and June 30, 2023, and for the three and nine month periods ended March 31, 2024 and 20 ...

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Q3 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Paula Savanti - Head of Investor Relations Federico Trucco - Chief Executive Officer Enrique Lopez Lecube - Chief Financial Officer Conference Call Participants Kristen Owen - Oppenheimer Ben Klieve - Lake Street Capital Markets Scott Fortune - ROTH MKM Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Bioceres Crop Solutions Fiscal Third Quarter 2024 Financial Results Con ...

One of the best stocks for financial freedom over the past 30 years is Monster Beverage (NASDAQ:MNST). Between Feb. 14, 1994, and Feb. 14, 2024, the energy drink maker’s stock appreciated around 200,000%. That’s $2,000 in gains for every dollar bet. That’s some capital gains bill.Combine a growing trend with solid management, and you have the makings of a 200-bagger.“Some of it is clearly right place, right time,” CNBC reported Stifel consumer and retail managing director Mark Astrachan’s comments in Februa ...

Financial Data and Key Metrics Changes - Total revenues for the second quarter of fiscal '24 reached $140 million, representing a nearly 50% improvement compared to the same quarter last year [41][86] - Net income improved by eightfold, and adjusted EBITDA for the quarter reached $24.1 million, a 134% increase compared to the year-ago period [41][25] - Overall gross profit was $51.5 million, a 46% increase over last year's number, with gross margin remaining roughly flat at almost 37% [88] Business Line Data and Key Metrics Changes - In crop nutrition, revenues increased by 49%, driven by a 61% increase in sales volumes of microbead fertilizers [87] - The seed and integrated product segment saw significant growth, almost doubling last year's sales number, primarily due to higher HB4 sales [5] - Crop protection revenues increased by 34% compared to last year, attributed to normalization of weather conditions leading to greater pest pressure [24] Market Data and Key Metrics Changes - The company reported a 49% revenue increase, reflecting strong performance across all segments despite a double-digit contraction in some key markets like Brazil [85][86] - HB4 soy hectares under the Identity Preserve Program were at 150% of last year's hectares, with a seven times expansion in Brazil [68] - The company maintained a healthy run rate of interest expenses with an annualized average cost of debt at around 7% [7] Company Strategy and Development Direction - The company is focused on execution and consolidating the integration of Marone, while remaining open to M&A opportunities [15] - There is a strong emphasis on improving the performance of HB4 wheat and expanding its market presence, particularly in Brazil [9][71] - The company aims to improve EBITDA by approximately $15 million in the upcoming fiscal year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current fiscal year, highlighting the ability to deliver consistent and profitable growth when market conditions are normal [86] - The company noted that the depreciation of the Argentine peso allowed for financial gains from hedging activities, contributing positively to the overall financial results [26][103] - Management acknowledged the challenges posed by the broader destocking process in several geographies but emphasized the strength of their innovative product portfolio [85] Other Important Information - The company was granted an additional patent by the USPTO that should protect the HB4 soy technology through at least 2042 [27][66] - The company reported a total financial debt of $223 million, down from $257 million in the prior fiscal year [7][70] Q&A Session Summary Question: What are the expectations for HB4 Soy in the next fiscal year? - Management feels confident about the progress in Brazil and believes it is moving at a faster pace than projected, but it may be too early to provide full visibility [97] Question: How did HB4 Soy perform during drought conditions in the U.S.? - The performance of HB4 Soy during drought conditions is still being assessed, as most activities are within the breeding program stage [110] Question: What is the nature of the new IP granted? - The new IP is a U.S. patent that adds to existing protections and covers the insertion site in the seed, allowing for a staggered approach to IP protection [106][107]

Sustainable agriculture aims to meet the current food and textile needs to ensure the “ability of future generations to meet their own needs.” With global food shortages and water scarcity in several regions, sustainable agriculture is more relevant than ever. It also implies a positive outlook for sustainable agriculture stocks in the coming years.Some of the key themes in sustainable agriculture include soil nutrition management, organic farming, precision agriculture and technology in agriculture. Of cou ...

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced today the release of the company’s global greenhouse gas emissions report, available here. The report takes inventory of the company´s fiscal year 2023 Scope 1 & 2 greenhouse gas emissions across all operations, spanning manufacturing plants, ...

F I S C A L a BIOCERES CROP SOLUTIONS 2 0 2 4 FIRST QUARTER 2024 Disclaimer Use of Non-IFRS Financial Measures Copyrights and Trademarks This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial instruments of the Company or any of its affiliates, and shall not form the basis of any contract, nor shall it be construed in any manner as a c ...

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Q1 2024 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Paula Savanti – Head of Investor Relations Federico Trucco – Chief Executive Officer Enrique Lopez Lecube – Chief Financial Officer Conference Call Participants Ben Klieve – Lake Street Capital Market Bobby Burleson – Canaccord Andre Adams – Oppenheimer Kemp Dolliver – Brookline Capital Markets Operator Hello, everyone, and welcome to today’s call Bioceres Crop Solutions Fiscal Firs ...

Fiscal First Quarter 2024 Financial and Operating Results [Financial & Business Highlights](index=2&type=section&id=FINANCIAL%20%26%20BUSINESS%20HIGHLIGHTS) Bioceres reported total revenues of $116.6 million and Adjusted EBITDA of $16.3 million for 1Q24, showing recovery from drought, alongside key operational achievements Financial & Business Highlights | Metric | 1Q24 | 1Q23 | % Change | | :--- | :--- | :--- | :--- | | Total Revenues | $116.6M | $127.1M | (8%) | | Adjusted EBITDA | $16.3M | $24.5M | (34%) | - A groundbreaking U.S. patent was awarded for the company's UHC® technology, which sets a new standard in biological nitrogen fixation for legumes[10](index=10&type=chunk)[14](index=14&type=chunk) - Construction of a new state-of-the-art adjuvant production plant in Londrina, Brazil was completed to expand the company's footprint in the Brazilian market[4](index=4&type=chunk) - The HB4 wheat harvest is underway in Argentina with favorable preliminary results compared to non-HB4 varieties, despite the season being affected by drought[30](index=30&type=chunk) [Management Review](index=2&type=section&id=MANAGEMENT%20REVIEW) Management noted a return to momentum with normalized weather, strong adjuvant and biostimulant sales, and significant growth in the Generation HB4 Program - The CEO stated that with normalized rain patterns, the company has regained momentum, which is expected to accelerate in subsequent quarters, contrasting with 1Q23's record performance that was partly due to pulling sales forward ahead of a historic drought[11](index=11&type=chunk)[7](index=7&type=chunk) - The CFO highlighted key positive trends in the quarter, including the recovery of adjuvant sales, growth from the UBP biostimulants platform, and margin expansion from the bioprotection portfolio[35](index=35&type=chunk) - The Generation HB4 Program is experiencing significant growth, with current acreage at **150% of the prior season**, including a six-fold increase in Brazil[34](index=34&type=chunk) [Detailed Financial Analysis](index=4&type=section&id=Detailed%20Financial%20Analysis) This section details the company's financial performance, including an 8% revenue decline, 13% gross profit decrease, and 34% Adjusted EBITDA reduction, primarily due to Crop Nutrition [Revenue Analysis](index=4&type=section&id=Revenue%20Analysis) Total revenue decreased 8% to $116.6 million, with Crop Protection down 11%, Seed and Integrated Products up 61%, and Crop Nutrition down 24% Revenue by Segment | Revenue by Segment | 1Q24 ($M) | 1Q23 ($M) | % Change | | :--- | :--- | :--- | :--- | | Crop protection | 55.9 | 63.0 | (11%) | | Seed and integrated products | 22.3 | 13.8 | 61% | | Crop nutrition | 38.3 | 50.3 | (24%) | | **Total revenue** | **116.6** | **127.1** | **(8%)** | - Crop Protection sales fell **11%** as the company exited low-margin third-party products, which offset a **32%** year-over-year increase in high-margin adjuvants[18](index=18&type=chunk)[40](index=40&type=chunk) - Seed and Integrated Product sales grew **61%**, primarily due to downstream sales of first-generation HB4 wheat inventories as grain to processors in the Generation HB4 program[20](index=20&type=chunk) - Crop Nutrition sales decreased **24%**, overshadowed by extraordinary sales of micro-beaded fertilizers in 1Q23 which benefited from high prices and concentrated seasonal sales[18](index=18&type=chunk)[44](index=44&type=chunk) [Gross Profit Analysis](index=5&type=section&id=Gross%20Profit%20Analysis) Total gross profit declined 13% to $45.0 million, with gross margin contracting to 38.6%, driven by a significant drop in Crop Nutrition Gross Profit by Segment | Gross Profit by Segment | 1Q24 ($M) | 1Q23 ($M) | % Change | | :--- | :--- | :--- | :--- | | Crop protection | 19.7 | 17.9 | 10% | | Seed and integrated products | 8.2 | 8.3 | (1%) | | Crop nutrition | 17.0 | 25.2 | (32%) | | **Total Gross profit** | **45.0** | **51.4** | **(13%)** | - Despite lower sales, Crop Protection gross profit increased by **10%** as the company shifted from low-margin products to higher-margin adjuvants and bioprotection products[24](index=24&type=chunk) - Crop Nutrition gross profit declined by **32%**, primarily due to lower sales of micro-beaded fertilizers and normalized gross margins compared to the unusually high margins in 1Q23[25](index=25&type=chunk) [Operating Expenses](index=5&type=section&id=Operating%20Expenses) SG&A expenses decreased 6% to $25.7 million due to synergies and cost controls, while R&D increased to $3.1 million for new product registrations - SG&A expenses (excluding D&A and other items) decreased by **6%** year-over-year to **$25.7 million**, driven by cost synergies realized in Pro Farm and cost control measures in Argentina[47](index=47&type=chunk)[27](index=27&type=chunk) - R&D expenses rose to **$3.1 million** from $2.2 million in 1Q23, mainly due to costs for registering Pro Farm products in South America and regulatory efforts for the Rinotec platform[73](index=73&type=chunk) [Adjusted EBITDA](index=6&type=section&id=Adjusted%20EBITDA) Adjusted EBITDA decreased 34% to $16.3 million, primarily due to lower gross profit, partially offset by SG&A savings and higher JV profits Adjusted EBITDA Reconciliation | Adjusted EBITDA Reconciliation | 1Q24 ($M) | 1Q23 ($M) | | :--- | :--- | :--- | | Gross profit | 45.0 | 51.4 | | SG&A (ex items) | (25.7) | (27.3) | | R&D (ex items) | (3.1) | (2.2) | | Share of profit from JVs | 1.5 | 0.8 | | Other | (2.6) | 0.5 | | **Adjusted EBITDA** | **16.3** | **24.5** | - The **$8.2 million** decrease in Adjusted EBITDA was primarily caused by a **$6.4 million** decline in gross profit, partially offset by **$1.6 million** in SG&A savings and a **$0.7 million** increase in profits from JVs[75](index=75&type=chunk) [Financial Income and Loss](index=7&type=section&id=Financial%20Income%20and%20Loss) The net financial loss improved slightly to $7.5 million from $8.1 million, driven by a 22% decrease in net interest expenses due to one-time efficiencies Financial Result Breakdown | Financial Result Breakdown | 1Q24 ($M) | 1Q23 ($M) | | :--- | :--- | :--- | | Net interest expenses and financial commissions | (4.0) | (5.1) | | Other non-cash financial result | (3.6) | (3.0) | | **Total Net Financial Result** | **(7.5)** | **(8.1)** | - Net interest expenses and commissions decreased by **$1.1 million** compared to the prior year, mainly explained by one-time financial efficiencies from Argentine subsidiaries[53](index=53&type=chunk) [Balance Sheet and Capitalization](index=8&type=section&id=Balance%20Sheet%20and%20Capitalization) Total financial debt was $226.4 million, with net debt at $183.0 million, and the Net Debt-to-LTM Adjusted EBITDA ratio improved to 2.51x Capitalization (as of Sep 30) | Capitalization (as of Sep 30) | 2023 ($M) | 2022 ($M) | | :--- | :--- | :--- | | Short-Term Debt | 100.7 | 74.7 | | Long-Term Debt | 125.7 | 153.1 | | Cash and Equivalents | (43.5) | (51.3) | | **Total Net Debt** | **183.0** | **176.6** | | **Net Debt / LTM Adj. EBITDA** | **2.51x** | **2.78x** | - The Net Debt-to-LTM Adjusted EBITDA ratio decreased to **2.51x** from 2.78x in 1Q23, driven by a **15%** increase in LTM Adjusted EBITDA[80](index=80&type=chunk) - Total financial debt stood at **$226.4 million**, nearly unchanged from $227.8 million in 1Q23, with short-term debt constituting **44%** of the total[79](index=79&type=chunk) [Appendix](index=10&type=section&id=Appendix) This section provides supplementary information, including definitions of non-IFRS measures, details on hyperinflationary accounting, and unaudited consolidated financial statements [Use of Non-IFRS Financial Information](index=10&type=section&id=Use%20of%20Non-IFRS%20Financial%20Information) The company defines Adjusted EBITDA as a non-IFRS measure, explaining its components and limitations for investors in assessing core operating performance - Adjusted EBITDA is defined as profit/(loss) exclusive of financial income/(costs), income tax, depreciation, amortization, share-based compensation, inventory purchase allocation, and one-time transactional expenses[66](index=66&type=chunk) - Management believes Adjusted EBITDA provides useful supplemental information to investors about trends in the company's core operating performance[109](index=109&type=chunk)[91](index=91&type=chunk) [Consolidated Financial Statements](index=13&type=section&id=Consolidated%20Financial%20Statements) This section presents the unaudited Consolidated Statement of Comprehensive Income, showing a $2.7 million net loss, and the Consolidated Statement of Financial Position with $840.7 million in total assets Statement of Comprehensive Income (3-months ended Sep 30) | Statement of Comprehensive Income (3-months ended Sep 30) | 2023 ($M) | 2022 ($M) | | :--- | :--- | :--- | | Total revenue | 116.6 | 127.1 | | Gross profit | 45.0 | 51.4 | | Operating profit | 5.3 | 17.0 | | **Profit/(loss) for the period** | **(2.7)** | **3.9** | Statement of Financial Position (as of Sep 30, 2023) | Statement of Financial Position (as of Sep 30, 2023) | Amount ($M) | | :--- | :--- | | Total current assets | 395.9 | | Total non-current assets | 444.8 | | **Total assets** | **840.7** | | Total current liabilities | 311.7 | | Total non-current liabilities | 195.9 | | **Total liabilities** | **507.6** | | **Total equity** | **333.1** |

● requirements of being a public company may strain our resources and distract our management; ● IT disruptions or failures in our operating system can affect our reputation and business; ● non-compliance with anti-corruption and anti-money laundering laws can subject us to criminal and civil liability; Risks Related to our Intellectual Property ● changes in Argentine and U.S. patent law could diminish the value of patents and impair our ability to protect our product candidates; Risks Related to Operating ...